P/E ratio for Armata Pharmaceuticals (ARMP)
P/E ratio as of May 2024 (TTM): -2.57
According to Armata Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.57282. At the end of 2022 the company had a P/E ratio of -1.14.
P/E ratio history for Armata Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.14 | -79.86% |
| 2021 | -5.65 | 169.2% |
| 2020 | -2.10 | 65.95% |
| 2019 | -1.26 | 119.65% |
| 2018 | -0.5757 | 86.97% |
| 2017 | -0.3079 | 79.93% |
| 2016 | -0.1711 | -86.84% |
| 2015 | -1.30 | -153.14% |
| 2014 | 2.45 | -374.13% |
| 2013 | -0.8929 | |
| 2008 | -0.2136 | -85.85% |
| 2007 | -1.51 | -4.97% |
| 2006 | -1.59 | -30.29% |
| 2005 | -2.28 | -73.53% |
| 2004 | -8.61 | -92.7% |
| 2003 | -118 | 1016.06% |
| 2002 | -10.6 | -82.73% |
| 2001 | -61.2 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.